0001415889-22-006727.txt : 20220617
0001415889-22-006727.hdr.sgml : 20220617
20220617161603
ACCESSION NUMBER: 0001415889-22-006727
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220615
FILED AS OF DATE: 20220617
DATE AS OF CHANGE: 20220617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MCCLUSKI STEPHEN C
CENTRAL INDEX KEY: 0001188728
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17999
FILM NUMBER: 221024041
MAIL ADDRESS:
STREET 1: 80 ARKAY DRIVE
CITY: HAUPPAUGE
STATE: NY
ZIP: 11788
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ImmunoGen, Inc.
CENTRAL INDEX KEY: 0000855654
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042726691
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 830 WINTER ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781)895-0600
MAIL ADDRESS:
STREET 1: 830 WINTER ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUNOGEN INC
DATE OF NAME CHANGE: 19920703
4
1
form4-06172022_010645.xml
X0306
4
2022-06-15
0000855654
ImmunoGen, Inc.
IMGN
0001188728
MCCLUSKI STEPHEN C
C/O IMMUNOGEN, INC.
830 WINTER STREET
WALTHAM
MA
02451
true
false
false
false
Deferred Share Unit
0
2022-06-15
4
A
0
15000
0
A
Common Stock
15000
105458
D
Stock Option (right to buy)
3.37
2022-06-15
4
A
0
44000
3.37
A
2032-06-15
Common Stock
44000
44000
D
The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date.
The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date.
/s/ Renee Lentini, Attorney-in-Fact
2022-06-17